Lab receives $30M funding to illuminate lung and ovarian cancers

A new funding announcement could lead to enhanced detection of lung and ovarian cancer through the use of intraoperative molecular imaging agents.

On Target Laboratories, a biotechnology company specializing in imaging agents for cancer surgery, has successfully secured $30 million in series C financing, which the company said will be used to significantly contribute to advancing the commercialization of CYTALUX, an FDA-approved molecular agent that illuminates lung and ovarian cancers. 

The funding was provided by new and existing investors H.I.G. Capital, the Hurvis Group, Johnson & Johnson Innovation, the Pension Fund of the Christian Church, 3B Future Health Fund, Elevate Ventures and Olympus Innovation Ventures.

“On Target Laboratories is at the forefront of a new wave of fluorescent agents that are game changers for surgical imaging,” Nacho Abia, chief strategy officer at Olympus said in a statement. “The ability of CYTALUX to illuminate lung and ovarian cancer during surgery is a stellar example of what we describe at Olympus as ‘making the invisible visible’.”

The illumination not only makes detecting new cancers easier, it also provides a guide for surgeons.

In addition to the funding, On Target Laboratories recently received a new technology add-on payment (NTAP) from the Centers for Medicare & Medicaid Services for the use of CYTALUX in ovarian and lung cancer surgery. The company said NTAP will provide hospitals with an additional payment of up to 65% of the average cost of CYTALUX.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.